Introduction
============

Hypertension is a major risk factor for cardiovascular disease. It has been estimated that the prevalence of hypertension is about 29.3% in general population and 66.3% in elderly ([@b46-vhrm-4-0847]; [@b66-vhrm-4-0847]). Blood pressure (BP) control is crucial to improve cardiovascular prognosis in hypertensive patients ([@b40-vhrm-4-0847]). In the US, data from the National Health and Nutrition Examination Survey show that only about one third of American hypertensive patients are adequately controlled ([@b17-vhrm-4-0847]). Although BP control is still far from optimal, in recent years it has markedly improved; as an example, in Spain, BP control has increased from less than 20% to the current 40% ([@b7-vhrm-4-0847]). However, this situation may worsen since the most recent recommendations have proposed more strict BP objectives for patients at high risk such as those with diabetes, or cardiovascular or renal disease in which BP goals should be \<130/80 mmHg ([@b40-vhrm-4-0847]). This is clinically very relevant, first, because current evidence shows that nowadays the majority of patients daily attended by physicians, regardless they are specialists or general practitioners, are at high or very high risk, and second, because the prevalence of obesity and diabetes is likely to grow in the near future, this situation will worsen ([@b8-vhrm-4-0847]; [@b58-vhrm-4-0847]).

[Figure 1](#f1-vhrm-4-0847){ref-type="fig"} shows the different BP control rates according to different cardiovascular risk conditions provided from a recently published survey that enrolled a total of 12,954 patients with hypertension assisted daily in primary care setting ([@b9-vhrm-4-0847], [@b10-vhrm-4-0847], [@b11-vhrm-4-0847]). As shown, when cardiovascular risk increases, a lower proportion of patients attain BP goals.

It has been reported that most patients with hypertension will need at least two antihypertensive drugs to achieve BP goals, mainly those patients at higher risk ([@b43-vhrm-4-0847]; [@b59-vhrm-4-0847]; [@b8-vhrm-4-0847]; [@b58-vhrm-4-0847]). A study that analyzed the number of antihypertensive drugs used in different clinical trials reported that the median of agents used for each patient was 2.8. Despite this, most of them did not achieve optimal BP objectives ([@b35-vhrm-4-0847]; [@b23-vhrm-4-0847]; [@b29-vhrm-4-0847]; [@b4-vhrm-4-0847]; [@b14-vhrm-4-0847]; [@b37-vhrm-4-0847]; UKPDS 38 2001; ALL-HAT investigators 2002; [@b19-vhrm-4-0847]). Although there is a growing awareness about the need of using combinations to attain BP goals in most patients, mainly in those at higher risk, their use in clinical practice is still far from desirable ([Figure 2](#f2-vhrm-4-0847){ref-type="fig"}) ([@b9-vhrm-4-0847], [@b10-vhrm-4-0847], [@b11-vhrm-4-0847]; [@b40-vhrm-4-0847]).

Rationale of combined therapy
=============================

Classically, guidelines for the management of arterial hypertension recommended "start low, go slow". This meant that treatment should be initiated at low doses and with slow increases, in order to avoid side effects, but assumed incorrectly that in most patients with hypertension there was only one underlying cause. However, current evidence shows that hypertension is caused by interacting multifactorial mechanisms, and this is more significant in high-risk patients ([@b44-vhrm-4-0847]).

As a result, to best treat these patients, it is necessary to use combinations of drugs with different mechanisms of action. Combined therapy can block counter-regulatory mechanisms and potentiate the antihypertensive efficacy beyond the additive response of each drug alone ([@b39-vhrm-4-0847]). Several trials have shown that when the titration of medication is very gradual, patients are at risk of presenting cardiovascular outcomes before BP goals are obtained, especially in those with diabetes or previous cardiovascular disease ([@b29-vhrm-4-0847]; [@b65-vhrm-4-0847]; [@b34-vhrm-4-0847]; [@b44-vhrm-4-0847]). The advantages of combination therapy are well documented: 1) Increased antihypertensive efficacy as a result of combining different mechanisms of action; 2) A lesser incidence of adverse effects because of the lower doses used and the possible compensatory responses; 3) Since fixed low-dose combinations are available, the treatment simplification may optimize compliance and, secondarily, enhance BP control; and 4) Starting treatment with a two-drug combination may allow BP goals to be achieved earlier than with only one antihypertensive drug ([@b40-vhrm-4-0847]).

In fact, the JNC-7 report and the European guidelines for the management of arterial hypertension recommend a more aggressive approach in some patients ([@b18-vhrm-4-0847]; [@b40-vhrm-4-0847]). The JNC-7 report suggests that it should be started from the beginning with two antihypertensive drugs in those patients with a systolic BP \>20 mmHg over BP goal and/or \>10 mmHg over the diastolic goal ([@b18-vhrm-4-0847]). European guidelines are more clear about this issue ([@b40-vhrm-4-0847]). Thus, as these recommendations suggest, combination therapy is necessary when monotherapy fails to attain BP objectives but also as first-line treatment in some situations, such as high or very high cardiovascular risk, when lower BP targets are required, or when BP elevations are marked ([@b40-vhrm-4-0847]).

In clinical practice there are numerous fixed-dose antihypertensive combination regimens: beta-blockers + hydrochlorothiazide (HCTZ), angiotensin converting enzyme inhibitors (ACEi) + HCTZ, angiotensin receptor blockers (ARB) + HCTZ, and calcium channel blockers (CCB) + ACEi ([@b12-vhrm-4-0847]). One of the most promising combinations is lercanidipine (a CCB) + enalapril (an ACEi).

Combining CCB and ACEi: beyond blood pressure control
=====================================================

Several randomized clinical trials and studies performed in conditions of daily clinical practice have shown that CCBs are potent antihypertensive drugs with a good tolerability not only in the general hypertensive population but also in high risk patients, alone or in combination ([@b62-vhrm-4-0847]; [@b38-vhrm-4-0847]; [@b5-vhrm-4-0847], [@b6-vhrm-4-0847]; [@b45-vhrm-4-0847]; [@b30-vhrm-4-0847]; [@b21-vhrm-4-0847]; [@b24-vhrm-4-0847], [@b25-vhrm-4-0847], [@b26-vhrm-4-0847]; [@b47-vhrm-4-0847]; [@b48-vhrm-4-0847]; [@b61-vhrm-4-0847]).

Lercanidipine is a third-generation vasoselective dihydropyridine (DHP) acting through the blockade of the L-type calcium channels in cell membranes ([@b31-vhrm-4-0847]; [@b41-vhrm-4-0847]; [@b22-vhrm-4-0847]; [@b28-vhrm-4-0847]). This drug has a high lipophilicity, which enables a slower and smooth onset and longer duration of action than other classic DHPs ([@b41-vhrm-4-0847]). Lercanidipine is highly selective for vascular smooth muscle because of the high proportion of L-type calcium channels in this tissue ([@b28-vhrm-4-0847]). The efficacy of lercanidipine has been evaluated in non-comparative and in comparative studies with other CCBs and different anti-hypertensive drugs, showing comparable effects in all the cases ([@b5-vhrm-4-0847], [@b6-vhrm-4-0847]; [@b33-vhrm-4-0847]; [@b36-vhrm-4-0847]; [@b16-vhrm-4-0847]; [@b56-vhrm-4-0847]). The effect of lercanidipine has also been successfully evaluated in severe or resistant hypertension, elderly subjects, and diabetics ([@b3-vhrm-4-0847]; [@b1-vhrm-4-0847]).

Moreover, some studies have suggested that lercanidipine may have anti-atherogenic effects beyond BP reductions ([@b60-vhrm-4-0847]; [@b50-vhrm-4-0847]; [@b15-vhrm-4-0847]). As an example, lercanidipine reduced by 35% (p \< 0.001) the levels of low-density lipoprotein cholesterol oxidation, measured as conjugated diene formation, in a hypertensive population with diabetes mellitus ([@b50-vhrm-4-0847]). Other benefits reported with lercanidipine are their renoprotective effects and favorable effects on lipid profile and glucose tolerance ([@b20-vhrm-4-0847]; [@b54-vhrm-4-0847]; [@b12-vhrm-4-0847]). Thus, a study that recruited 203 chronic renal failure patients (creatinine \> 1.4 mg/dL for males, creatinine \> 1.2 mg/dL for females, or creatinine clearance \< 70 mL/min) showed that lercanidipine had a high antihypertensive effect with a good tolerability profile in patients with renal failure. Moreover, an improvement in renal function assessed by creatinine clearance was described ([@b54-vhrm-4-0847]). On the other hand, lercanidipine has been shown to have neutral or favorable effects on lipid profile and to enhance glucose tolerance and to reduce fasting blood glucose and glycosylated haemoglobin in diabetics with hypertension ([@b3-vhrm-4-0847]; [@b28-vhrm-4-0847]). Lercanidipine is a well tolerated drug with a low adverse events rate due to its long-lasting and vascular-selective calcium entry-blocking activity, while sympathetic activation and reflex tachycardia is not induced ([@b22-vhrm-4-0847]). As a result, the overall adverse events rate is lower than that observed with other DHPs ([@b16-vhrm-4-0847]; [@b12-vhrm-4-0847]).

The renin-angiotensin-aldosterone system (RAAS) plays a key role in regulating blood volume and systemic vascular resistance. The over-activation of this system, especially through the excessive production of its effector peptide, angiotensin II, has been related to the genesis and development of cardiovascular diseases ([@b12-vhrm-4-0847]). Enalapril, an ACEi, is an orally administered prodrug that is hydrolyzed to the active form enalaprilat, which reduces the plasma levels of angiotensin II ([@b64-vhrm-4-0847]). This reduction of angiotensin II results in peripheral vasodilatation and reduced vascular resistance, leading to a decrease in BP values ([@b28-vhrm-4-0847]). Enalapril is a dose-dependent antihypertensive drug, with the maximum effect occurring after 6--8 hours of administration and a total effect duration of 24--36 hours ([@b64-vhrm-4-0847]). Enalapril has shown to be an effective antihypertensive agent, with positive effects on cardiovascular risk factors and organ damage ([@b63-vhrm-4-0847]; [@b51-vhrm-4-0847], [@b32-vhrm-4-0847]; [@b57-vhrm-4-0847]). Thus, enalapril reduced carotid artery intima-media thickness progression, an independent risk factor for cardiovascular and cerebrovascular disease ([@b32-vhrm-4-0847]). Moreover, in a randomized, double-blind, 6-year trial in patients with diabetes and normoalbuminuria at baseline, enalapril reduced the development of microalbuminuria ([@b51-vhrm-4-0847]).

The combination of CCB and ACEi is especially effective due to their complementary mechanisms that enhance the antihypertensive efficacy with a low side effects rate ([@b39-vhrm-4-0847]). CCBs are potent vasodilators that induce reflex activation of the sympathetic system and RAAS. As a result, the use of an ACEi may buffer this excessive activation. Moreover, since CCBs promote a negative sodium balance and an increase of angiotensin II levels, this may reinforce the antihypertensive effect of ACEis ([@b27-vhrm-4-0847]). On the other hand, the concomitance of both treatments may reduce the presence of adverse events, mainly the peripheral oedema ([@b42-vhrm-4-0847]). Mechanistically, the development of lower extremity oedema during calcium entry blockade is due to an increase in intracapillary pressure, as a consequence of a selective diminution of the precapillary arteriolar tone. Interestingly, ACEis reduce the lower extremity oedema caused by CCBs, most likely because of their ability to dilate both the arterial vascular bed and the venous capacitance vessels ([@b67-vhrm-4-0847]; [@b27-vhrm-4-0847]).

Fixed combination lercanidipine plus enalapril: current evidence
================================================================

Several trials have demonstrated the benefits of the fixed combination of lercanidipine and enalapril ([@b52-vhrm-4-0847], [@b53-vhrm-4-0847]; [@b1-vhrm-4-0847]; [@b49-vhrm-4-0847]). In a trial performed in hypertensive patients who were nonresponders to lercanidipine, after 12 weeks of treatment with fixed combination lercanidipine plus enalapril, a significantly greater proportion of patients with this combination normalized their BP compared with patients treated with lercanidipine in monotherapy (22% vs 12%, p = 0.012) ([@b52-vhrm-4-0847]). Similarly, in another study developed in patients with hypertension who were nonresponders to enalapril, after 12 weeks of treatment with this fixed combination, there was a trend to a better BP control in the population treated with the fixed combination compared with enalapril in monotherapy (24% vs 17%, p = NS) ([@b53-vhrm-4-0847]).

More recently, a double-blind, placebo-controlled, four-way balanced design crossover study included hypertensive patients aged 60--85 years with mean office-measured sitting systolic BP 160--179 mmHg and daytime ambulatory systolic BP ≥135 mmHg ([@b49-vhrm-4-0847]). After a 2-week run-in period, during which previous medications were discontinued, each patient were randomly allocated to lercanidipine 10 mg, enalapril 20 mg, lercanidipine 10 mg plus enalapril 20 mg, or placebo. Of the 75 patients randomized, 62 completed the study. At study end, office BP was measured and a 24-hour ambulatory BP monitoring was performed. The administration of placebo, lercanidipine, enalapril, and lercanidipine plus enalapril was associated with a mean 24-hour systolic BP of 144, 137, 133, and 127 mmHg, respectively. All active treatments significantly reduced the mean 24-hour BP compared with placebo, but the combination lercanidipine plus enalapril was significantly more effective than the active components taken in monotherapy. Similarly, office systolic BP was significantly more reduced with the combination than with the monotherapies. A higher proportion of patients treated with the combination lercanidipine plus enalapril achieved BP goals compared with lercanidipine and enalapril alone (45% vs 18% vs 19%, respectively).

The combination lercanidipine plus enalapril has been shown to be effective not only in the general hypertensive population but also in high-risk patients, such as those with diabetes. A controlled clinical trial investigated the efficacy of lercanidipine vs HCTZ as add-on therapy in diabetic patients with uncontrolled hypertension on enalapril monotherapy ([@b1-vhrm-4-0847]). A total of 174 patients with well-controlled diabetes and mild to moderate hypertension were included in a 2-week placebo run-in followed by 4 weeks on enalapril 20 mg. Subsequently, 135 non-responders were randomized to 20 weeks of double-blind add-on therapy to enalapril with either lercanidipine 10 mg (n = 69) or HCTZ 12.5 mg (n = 66). BP response rates reached 69.6% on enalapril plus lercanidipine compared with 53.6% on enalapril plus HCTZ (p = NS) and BP control was attained in 30.4% of patients on lercanidipine add-on and in 23.2% of those randomized to HCTZ add-on (p = NS). [Figure 3](#f3-vhrm-4-0847){ref-type="fig"} summarizes BP control rates achieved by the combination lercanidipine plus enalapril in different clinical trials.

The combination lercanidipine plus enalapril was well tolerated in all clinical trials, with a similar rate of side effects than the drugs in monotherapy ([@b52-vhrm-4-0847] [@b53-vhrm-4-0847]; [@b1-vhrm-4-0847]; [@b49-vhrm-4-0847]). Although infrequent, the most prevalent adverse events related to the use of the combination lercanidipine plus enalapril were cough, dizziness, and vertigo. Interestingly, no clinically significant differences in heart rate were observed between groups and 24-hour heart rate remained stable under all treatments ([@b49-vhrm-4-0847]). The absence of negative effects of the combination on lipid and glucose metabolism appears an added advantage in the treatment of hypertensive population ([@b28-vhrm-4-0847]).

Conclusions and future perspectives
===================================

Most patients with hypertension often require more than one drug to achieve BP goals. The most recent European guidelines clearly establish that combination therapy is recommended as first-line therapy in certain situations, such as marked BP elevations, high or very high-risk patients, or when BP targets are lower ([@b40-vhrm-4-0847]). Clinical trials have shown that the combination lercanidipine plus enalapril is an effective and well-tolerated fixed-dose antihypertensive combination. As expected, it provides greater antihypertensive efficacy than either component taken as monotherapy. But to date studies assessing the effects of lercanidipine plus enalapril in reversing left ventricular hypertrophy or progression of renal disease, or improving clinical outcomes in hypertensive patients are still warranted.
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